1.
Mobile phone technologies improve adherence to antiretroviral treatment in a resource-limited setting: a randomized controlled trial of text message reminders
by POP-ELECHES, Cristian
AIDS (London), 2011, Vol.25 (6), p.825-834
2.
Histone methyltransferase inhibitors induce HIV-1 recovery in resting CD4+ T cells from HIV-1-infected HAART-treated patients
by BOUCHAT, Sophie
AIDS (London), 2012, Vol.26 (12), p.1473-1482
3.
TB-IRIS, T-cell activation, and remodeling of the T-cell compartment in highly immunosuppressed HIV-infected patients with TB
by Haridas, Viraga
AIDS (London), 2015-01-28, Vol.29 (3), p.263-273
4.
Emerging technologies for point-of-care CD4 T-lymphocyte counting
by Boyle, David S
Trends in biotechnology (Regular ed.), 2011, Vol.30 (1), p.45-54
5.
Effect of selenium supplementation on CD4+ T-cell recovery, viral suppression and morbidity of HIV-infected patients in Rwanda: a randomized controlled trial
by Kamwesiga, Julius
AIDS (London), 2015-06-01, Vol.29 (9), p.1045-1052
6.
Better Physician‐Patient Relationships Are Associated with Higher Reported Adherence to Antiretroviral Therapy in Patients with HIV Infection
by Schneider, John
Journal of general internal medicine : JGIM, 2004-11, Vol.19 (11), p.1096-1103
7.
Population-based metrics for the timing of HIV diagnosis, engagement in HIV care, and virologic suppression
by DOMBROWSKI, Julia C
AIDS (London), 2012, Vol.26 (1), p.77-86
8.
HIV-1 pol gene polymorphism and antiretroviral resistance mutations in treatment-naïve adult patients in French Guiana between 2006 and 2012
by Darcissac, Edith
AIDS research and human retroviruses, 2016, Vol.32 (ja), p.801-811
9.
Social capital and HIV Competent Communities: The role of community groups in managing HIV/AIDS in rural Zimbabwe
by Campbell, Catherine
AIDS care, 2013-06-20, Vol.25 (sup1), p.S114-S122
10.
Optimal Recall Period and Response Task for Self-Reported HIV Medication Adherence
by Lu, Minyi
AIDS and behavior, 2007-06-19, Vol.12 (1), p.86-94
11.
Peer counselors' role in supporting patients' adherence to ART in Ethiopia and Uganda
by Gusdal, Annelie K.
AIDS care, 2011-06-01, Vol.23 (6), p.657-662
12.
First-line antiretroviral therapy with nevirapine versus lopinavir-ritonavir based regimens in a resource-limited setting
by CLUMECK, Nathan
AIDS (London), 2014, Vol.28 (8), p.1143-1153
13.
Gender differences in antiretroviral treatment outcomes of HIV patients in rural Uganda
by Kipp, Walter
AIDS care, 2010-03-01, Vol.22 (3), p.271-278
14.
Defining total-body AIDS-virus burden with implications for curative strategies
by Estes, Jacob D
Nature medicine, 2017-11, Vol.23 (11), p.1271-1276
15.
Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs
by Altice, Frederick L, Prof
The Lancet (British edition), 2010, Vol.376 (9738), p.367-387
16.
Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals
by Bar-On, Yotam
Nature medicine, 2018-11, Vol.24 (11), p.1701-1707
17.
Low Prevalence of Transmitted HIV Type 1 Drug Resistance Among Antiretroviral-Naive Adults in a Rural HIV Clinic in Kenya
by Hassan, Amin S.
AIDS research and human retroviruses, 2013-01-01, Vol.29 (1), p.129-135
18.
HIV-hepatitis B virus coinfection: epidemiology, pathogenesis, and treatment
by Singh, Kasha P
AIDS (London), 2017-09-24, Vol.31 (15), p.2035-2052
19.
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised,...
by Sax, Paul E, Dr Prof
The Lancet (British edition), 2015, Vol.385 (9987), p.2606-2615
20.
Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinic
by Caskey, Marina
Nature medicine, 2019-04, Vol.25 (4), p.547-553
